AstraZeneca: European Agency Accepts Variation to Application for Tagrisso
November 28 2017 - 2:45AM
Dow Jones News
By Adria Calatayud
AstraZeneca PLC (AZN.LN) said Tuesday that the European
Medicines Agency has accepted a variation to its
marketing-authorization application for Tagrisso, for treatment of
adult patients with locally-advanced or metastatic non-small cell
lung cancer.
The pharmaceutical company said the drug application, which is
an epidermal growth factor receptor inhibitor, was based on data
from the phase 3 trial, in which Tagrisso significantly improved
progression-free survival compared to current treatments.
On Monday, AstraZeneca reported the submission of a supplemental
new drug application to Japan's Pharmaceuticals and Medical Devices
Agency for the use of Tagrisso.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
November 28, 2017 02:30 ET (07:30 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
